{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["26(4)"],"submitter":["Guo H"],"pubmed_abstract":["SARS-CoV-2 Omicron BA.2.75 subvariant has evolved to a series of progeny variants carrying several additional mutations in the receptor-binding domain (RBD). Here, we investigated whether and how these single mutations based on BA.2.75 affect the neutralization of currently available anti-RBD monoclonal antibodies (mAbs) with well-defined structural information. Approximately 34% of mAbs maintained effective neutralizing activities against BA.2.75, consistent with those against BA.2, BA.4/5, and BA.2.12.1. Single additional R346T, K356T, L452R, or F486S mutations further facilitated BA.2.75-related progeny variants to escape from broadly neutralizing antibodies (bnAbs) at different degree. Only LY-CoV1404 (bebtelovimab) displayed a first-class neutralization potency and breadth against all tested Omicron subvariants. Overall, these data make a clear connection between virus escape and antibody recognizing antigenic epitopes, which facilitate to develop next-generation universal bnAbs against emerging SARS-CoV-2 variants."],"journal":["iScience"],"pagination":["106283"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9969747"],"repository":["biostudies-literature"],"pubmed_title":["Additional mutations based on Omicron BA.2.75 mediate its further evasion from broadly neutralizing antibodies."],"pmcid":["PMC9969747"],"pubmed_authors":["Jiang J","Zhang Z","Guo H","Ge X","Zhou B","Cheng L","Shen S","Fan Q","Ju B"],"additional_accession":[]},"is_claimable":false,"name":"Additional mutations based on Omicron BA.2.75 mediate its further evasion from broadly neutralizing antibodies.","description":"SARS-CoV-2 Omicron BA.2.75 subvariant has evolved to a series of progeny variants carrying several additional mutations in the receptor-binding domain (RBD). Here, we investigated whether and how these single mutations based on BA.2.75 affect the neutralization of currently available anti-RBD monoclonal antibodies (mAbs) with well-defined structural information. Approximately 34% of mAbs maintained effective neutralizing activities against BA.2.75, consistent with those against BA.2, BA.4/5, and BA.2.12.1. Single additional R346T, K356T, L452R, or F486S mutations further facilitated BA.2.75-related progeny variants to escape from broadly neutralizing antibodies (bnAbs) at different degree. Only LY-CoV1404 (bebtelovimab) displayed a first-class neutralization potency and breadth against all tested Omicron subvariants. Overall, these data make a clear connection between virus escape and antibody recognizing antigenic epitopes, which facilitate to develop next-generation universal bnAbs against emerging SARS-CoV-2 variants.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Apr","modification":"2026-05-28T11:27:15.374Z","creation":"2025-02-19T03:26:38.168Z"},"accession":"S-EPMC9969747","cross_references":{"pubmed":["36925722"],"doi":["10.1016/j.isci.2023.106283"]}}